In the complex architecture of the human liver, researchers have long understood that the organ is not a monolithic block of tissue, but a sophisticated ecosystem of diverse cell types working in concert to filter blood, regulate metabolism, and detoxify the body. However, a recent breakthrough from the University of Michigan Life Sciences Institute has revealed that in the presence of severe disease, the liver creates a new kind of liver cell that may actually serve as a protective mechanism against further damage.
The study, published in the Journal of Clinical Investigation, identifies a unique cluster of hepatocytes—the primary functional cells of the liver—that appear exclusively in livers affected by metabolic dysfunction-associated steatohepatitis (MASH). While the presence of these cells is a marker of disease, their behavior suggests they may be the body’s attempt to adapt to metabolic stress, offering a potential new pathway for therapeutic intervention in a condition that currently lacks a wide array of targeted treatments.
MASH represents a severe progression of metabolic dysfunction-associated steatotic liver disease (MASLD). While MASLD involves the accumulation of fat in the liver, MASH is characterized by inflammation and cellular damage. This advanced stage is particularly concerning because it affects an estimated 5% to 10% of the adult population in the United States (National Institutes of Health) and can lead to irreversible cirrhosis and liver cancer if left unchecked.
Beyond the Three Zones: Discovering a New Cellular Identity
To understand why this discovery is significant, one must first understand how the liver is normally organized. Traditionally, medical science has categorized hepatocytes into three distinct “zones” based on their location and the specific genes they express. These zones are tailored to different specialized functions, ensuring that the liver can handle a variety of metabolic tasks simultaneously.
Researchers in the laboratory of Jiandie Lin, a professor of cell and developmental biology at the University of Michigan, utilized gene expression signatures to analyze individual hepatocytes from both healthy livers and those with MASH. Their goal was to identify specific cell types that could signal an increased risk of disease progression.
“Traditionally, hepatocytes are divided into three zones based on location-specific gene expression patterns that are tailored to specialized function,” Lin explained. “What was a little bit surprising when we analyzed the data is that, in addition to these three groups of hepatocytes, we found a new cluster of cells with a unique identity. And that particular group of cells only showed up in the MASH liver.”
The Paradox of Cellular Senescence
The most striking characteristic of this new cell cluster is that it displays signatures of cellular senescence. In medical terms, senescence is a state where a cell effectively stops dividing but does not die. These “zombie cells” typically linger in the tissue and are generally viewed as detrimental; they often secrete pro-inflammatory signals that interfere with normal tissue function and contribute to the progression of various age-related and metabolic diseases.
However, the Michigan team discovered a surprising twist. Within these senescent MASH hepatocytes, there was unusual activity from a gene called Themis. Under normal circumstances, Themis encodes a protein (THEMIS) that is active in T cells—a type of immune cell—but remains dormant in healthy liver cells.
In both human and mouse livers affected by MASH, the expression of Themis was strongly increased, ranking as one of the most highly activated genes in these specific disease-associated cells. This led the researchers to a critical question: was the activation of THEMIS causing the damage, or was the liver activating this pathway to protect itself from metabolic stress?
Testing the Protective Power of THEMIS
To determine whether THEMIS was a villain or a hero in the context of liver disease, the researchers employed mouse models to isolate the protein’s effects. By specifically deleting Themis from the hepatocytes of mice, the team observed a marked decline in liver health. Without the THEMIS protein, the livers showed significantly greater signs of injury, increased inflammation, heightened senescence, and more severe fibrosis—the scarring of liver tissue that leads to cirrhosis.
Conversely, when the researchers increased THEMIS levels in the hepatocytes, the results were opposite. They observed a decrease in cellular senescence and an overall improvement in protection against liver injury and the progression of MASH.
Xiaoxue Qiu, the study’s lead author and a former researcher in the Lin lab now heading her own laboratory at the University of Minnesota, noted the rarity of this find. “It’s pretty exciting, because only a couple of other studies have identified this cell population, and not much was really known about what these cells are doing in disease,” Qiu stated. “And now we are seeing that Themis is a key regulator of hepatocyte senescence and that manipulating this subtype of disease-associated hepatocytes can have a major impact on disease progression.”
Clinical Implications: A New Therapeutic Target?
For patients living with MASLD and MASH, the implications of this research are promising. Because MASH is often asymptomatic until it reaches an advanced stage, finding biological “switches” that can stop the progression toward cirrhosis is a high priority for global health.
The discovery that the THEMIS pathway can mitigate liver injury suggests that future therapies could focus on modulating this specific signaling pathway. Rather than simply trying to eliminate senescent cells—a common goal in “senolytic” research—the focus may shift toward enhancing the protective mechanisms that these cells employ to survive metabolic stress.
Professor Lin believes these findings provide a necessary starting point to identify other drivers of liver damage and to evaluate whether the THEMIS pathway can be developed into a viable therapeutic target for MASH patients.
Key Takeaways for Patients and Providers
- New Cell Discovery: Researchers identified a unique cluster of hepatocytes that appear only in MASH-affected livers.
- The THEMIS Protein: While usually found in immune cells, THEMIS is activated in MASH hepatocytes and appears to protect the liver from severe injury.
- Senescence Role: While cellular senescence is typically harmful, the THEMIS-regulated response in these cells may help the liver adapt to metabolic stress.
- Future Outlook: This research opens the door for new drug targets that could leisurely or stop the progression of MASH toward liver cancer and cirrhosis.
The research was a collaborative effort involving scientists from the University of Michigan and the University of Pittsburgh School of Medicine, with funding provided by the National Institutes of Health (NIH), the American Heart Association, and the UM Diabetes Research Center. All animal procedures were conducted under the approval of the Institutional Animal Care and Use Committee at the University of Michigan.
As we move toward more personalized medicine, the ability to identify and manipulate specific cell subtypes within a diseased organ marks a significant shift in how we approach chronic liver conditions. While human clinical trials are not yet underway for THEMIS-based therapies, the mapping of this protective pathway provides a blueprint for the next generation of hepatology treatments.
For those seeking more information on managing metabolic liver health, the National Institutes of Health provides updated guidelines on the diagnosis and management of MASLD and MASH.
World Today Journal will continue to monitor the development of THEMIS-targeted research as it moves from mouse models toward human application. We invite our readers to share this update and leave their thoughts on medical innovation in the comments below.